Back to Search Start Over

Cancers and erectile dysfunction: a Mendelian randomization study.

Authors :
Yang G
Xiong Y
Wang Z
Wang J
Chen Y
Zhang H
Source :
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Nov 06; Vol. 15, pp. 1417830. Date of Electronic Publication: 2024 Nov 06 (Print Publication: 2024).
Publication Year :
2024

Abstract

Purpose: Cancer often coexists with erectile dysfunction, yet the causal relationship between them remains unclear. This study aims to investigate the causal link between tumors and ED through Mendelian randomization.<br />Method: Data on 13 different cancers, including lung cancer, colorectal cancer, testicular cancer, lymphoma, esophageal cancer, pancreatic cancer, thyroid cancer, bladder cancer and brain cancer were collected from various databases. ED data, comprising 2,205 cases and 164,104 controls, were sourced from the FinnGen project. Primary methods for MR analysis included IVW, MR-Egger, weighted median, and weighted mode.<br />Results: IVW results revealed associations between colorectal cancer (OR=1.17;95% CI 1.02-1.13, p=0.0252), prostate cancer (OR=1.63;95% CI 1.52-1.75, p<0.001) and liver cancer (OR=0.93;95% CI 0.88 -0.99, p=0.012) with ED.<br />Conclusion: Mendelian randomization analysis supports that prostate cancer and colorectal cancer are associated with an increased risk of Erectile Dysfunction, whereas liver cancer is linked to a decreased risk of ED. No evidence suggests that ED contributes to an increased risk of prostate cancer.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2024 Yang, Xiong, Wang, Wang, Chen and Zhang.)

Details

Language :
English
ISSN :
1664-2392
Volume :
15
Database :
MEDLINE
Journal :
Frontiers in endocrinology
Publication Type :
Academic Journal
Accession number :
39568814
Full Text :
https://doi.org/10.3389/fendo.2024.1417830